Published on

Medicine – Chronic Lymphocytic Leukaemia (CLL)

Chronic lymphocytic leukaemia (CLL) is a mature B-cell lymphoproliferative malignancy characterised by the progressive accumulation of clonal, usually small and mature-appearing lymphocytes in the peripheral blood, bone marrow and lymphoid tissues.

CLL is typically an indolent leukaemia and is one of the most common leukaemias affecting older adults in Western populations.

Many patients remain asymptomatic for years and do not require immediate treatment.

Important Clinical Principle

CLL commonly presents as an incidental finding of persistent lymphocytosis in an older adult. The characteristic peripheral blood film shows small mature-looking lymphocytes and smudge cells.

1. Pathophysiology

CLL develops from the clonal expansion and accumulation of mature B lymphocytes.

These cells have impaired apoptosis and receive survival signals from the surrounding tissue microenvironment.

Malignant lymphocytes may accumulate within:

  • Peripheral blood.
  • Bone marrow.
  • Lymph nodes.
  • Spleen.
  • Liver.

Pathophysiology Flowchart

Clonal B-Lymphocyte Expansion and Accumulation Peripheral Blood Persistent Lymphocytosis Lymphoid Tissue Infiltration Lymphadenopathy / Splenomegaly Possible Advanced Disease Bone Marrow Failure Anaemia / Thrombocytopenia Not all patients progress
Important Clarification: CLL does not always progress through a fixed sequence of lymphocytosis, lymphadenopathy, hepatosplenomegaly and marrow failure. Some patients remain asymptomatic indefinitely.

2. Clinical Features

A. Incidental Diagnosis

Many patients are diagnosed incidentally when routine blood investigations reveal an elevated lymphocyte count.

CLL may remain asymptomatic for prolonged periods.

B. Persistent Lymphocytosis

Persistent absolute lymphocytosis is a characteristic finding.

The diagnostic threshold for CLL is generally at least 5 × 109/L clonal B lymphocytes in peripheral blood for at least three months, confirmed by flow cytometry.

A lower clonal B-cell count without other disease features may represent monoclonal B-cell lymphocytosis (MBL).

C. Lymphadenopathy

Lymphadenopathy may develop as malignant lymphocytes accumulate within lymph nodes.

Typical features include:

  • Painless lymph node enlargement.
  • Rubbery lymph nodes.
  • Cervical lymphadenopathy.
  • Axillary lymphadenopathy.
  • Inguinal lymphadenopathy.

D. Hepatosplenomegaly

Splenomegaly and hepatomegaly may occur with increasing disease burden.

Patients may experience abdominal fullness or early satiety.

E. Bone Marrow Failure

Advanced marrow infiltration may cause:

  • Anaemia: Fatigue, pallor and dyspnoea.
  • Thrombocytopenia: Bruising or bleeding.
  • Neutropenia: Increased susceptibility to infection.

F. Other Manifestations

  • Recurrent infections due to hypogammaglobulinaemia and immune dysfunction.
  • Autoimmune haemolytic anaemia.
  • Immune thrombocytopenia.
  • Constitutional symptoms, including fever, night sweats and weight loss.
  • Fatigue and reduced exercise tolerance.

3. Peripheral Blood Film

The classical peripheral blood film demonstrates small, mature-looking lymphocytes with clumped chromatin and smudge cells (smear cells).

Characteristic Blood Film Findings

  • Increased numbers of small lymphocytes.
  • Round nuclei with densely clumped chromatin.
  • Scant cytoplasm.
  • Smudge cells caused by disruption of fragile lymphocytes during smear preparation.

Blood Film Schematic

Mature lymphocyte Smudge cell

Simplified educational illustration; not an actual peripheral blood film.

Examination Pearl: Smudge cells are characteristic but not specific for CLL. The diagnosis requires confirmation of a clonal B-cell population by flow cytometry.

4. Investigations and Diagnosis

Investigation Typical Finding or Purpose
Full blood countPersistent absolute lymphocytosis
Peripheral blood filmSmall mature lymphocytes and smudge cells
Flow cytometryConfirms clonal B-cell population
ImmunophenotypingTypically CD19+, CD5+, CD23+, with weak CD20 and surface immunoglobulin
FISH / molecular testingIdentifies prognostic and treatment-relevant abnormalities
Immunoglobulin levelsMay show hypogammaglobulinaemia
Direct antiglobulin testAssesses suspected autoimmune haemolysis
Bone marrow biopsyNot routinely required for diagnosis

Important Molecular Findings

  • del(13q): Often associated with a more favourable prognosis when isolated.
  • Trisomy 12: Intermediate or variable prognostic significance.
  • del(11q): Historically associated with more aggressive disease.
  • del(17p) or TP53 mutation: High-risk disease and important for treatment selection.
  • IGHV mutation status: Important prognostic and treatment-selection marker.

Diagnostic Flowchart

Persistent Lymphocytosis Often discovered incidentally Peripheral Blood Film Mature lymphocytes / smudge cells Flow Cytometry Clonal CD5+ / CD23+ B cells Clinical Staging Rai / Binet and risk assessment Management Decision Observe or treat active disease Based on established criteria

5. Staging of CLL

Two commonly used staging systems are the Rai and Binet classifications.

A. Rai Staging

Stage Clinical Findings
0Lymphocytosis only
ILymphocytosis with lymphadenopathy
IILymphocytosis with splenomegaly and/or hepatomegaly
IIIDisease-related anaemia (haemoglobin below 11 g/dL)
IVDisease-related thrombocytopenia (platelets below 100 × 109/L)

B. Binet Staging

Stage Criteria
AFewer than three involved lymphoid areas, without anaemia or thrombocytopenia
BThree or more involved lymphoid areas, without anaemia or thrombocytopenia
CHaemoglobin below 10 g/dL and/or platelets below 100 × 109/L attributable to disease

6. Management

Not every patient with CLL requires treatment.

A. Active Surveillance (Watchful Waiting)

Asymptomatic patients without active or progressive disease are usually managed with observation.

Follow-up includes:

  • Periodic clinical assessment.
  • Monitoring lymph node and spleen enlargement.
  • Full blood counts.
  • Assessment for constitutional symptoms and complications.

Early treatment has not demonstrated an overall survival benefit for most asymptomatic patients who do not meet established treatment criteria.

B. Indications for Treatment

Treatment is considered for active or progressive disease, including:

  • Progressive bone marrow failure.
  • Massive, symptomatic or progressive lymphadenopathy.
  • Massive, symptomatic or progressive splenomegaly.
  • Rapidly progressive lymphocytosis meeting established criteria.
  • Significant constitutional symptoms attributable to CLL.
  • Autoimmune cytopenias poorly responsive to standard therapy.
  • Symptomatic extranodal disease.
Important Examination Point: An elevated lymphocyte count alone does not necessarily indicate a need for treatment.

C. Modern Targeted Therapy

Contemporary CLL treatment commonly uses targeted agents selected according to TP53 status, comorbidities, treatment goals and local availability.

Drug Class Examples
BTK inhibitorsAcalabrutinib, zanubrutinib, ibrutinib
BCL2 inhibitorVenetoclax
Anti-CD20 antibodiesObinutuzumab, rituximab

Venetoclax-based therapy requires careful assessment and prevention of tumour lysis syndrome.

D. Historical Treatments

Traditional treatment options included:

  • Observation without immediate therapy.
  • Chlorambucil: An oral alkylating chemotherapy agent.
  • Radiotherapy: Occasionally used for local symptom control.

Chlorambucil is no longer a preferred first-line option for most patients where modern targeted treatments are available. Radiotherapy has a limited, mainly palliative role.

Management Flowchart

Confirmed CLL Assess symptoms and disease activity Inactive CLL No treatment criteria met Active CLL Treatment criteria met Watchful Waiting Clinical monitoring Periodic blood counts Assess progression Treatment BTK inhibitor or venetoclax-based regimen Individualised selection Ongoing Follow-Up

7. Important Complications

A. Recurrent Infections

CLL-associated immune dysfunction and hypogammaglobulinaemia increase susceptibility to infections.

B. Autoimmune Cytopenias

Autoimmune haemolytic anaemia and immune thrombocytopenia may occur.

C. Richter Transformation

Richter transformation refers to the development of an aggressive lymphoma, most commonly diffuse large B-cell lymphoma, in a patient with CLL.

It should be suspected when there is:

  • Rapidly enlarging lymphadenopathy.
  • New constitutional symptoms.
  • Markedly elevated LDH.
  • Sudden clinical deterioration.

8. High-Yield Examination Summary

Feature Key Point
DiseaseMature B-cell lymphoproliferative malignancy
Typical ageOlder adults
Clinical courseOften indolent
Common presentationIncidental lymphocytosis
Blood filmSmall mature lymphocytes and smudge cells
ImmunophenotypeCD5+, CD19+, CD23+
Diagnostic threshold≥5 × 109/L clonal B cells for ≥3 months
Organ involvementLymph nodes, spleen, liver, bone marrow
Immune complicationHypogammaglobulinaemia
Autoimmune complicationAutoimmune haemolytic anaemia
TransformationRichter transformation
Initial managementWatchful waiting if asymptomatic and inactive
Modern treatmentTargeted agents, including BTK or BCL2 inhibitors

9. Key Examination Pearls

  • CLL is a typically indolent mature B-cell malignancy affecting older adults.
  • Many cases are discovered incidentally following routine blood tests.
  • Persistent lymphocytosis is a characteristic laboratory finding.
  • Small mature-appearing lymphocytes and smudge cells are typical blood film findings.
  • CD5 and CD23 coexpression on clonal B cells is characteristic.
  • Lymphadenopathy, hepatosplenomegaly and marrow failure may develop with progression.
  • Hypogammaglobulinaemia predisposes to recurrent infections.
  • Autoimmune haemolytic anaemia is a recognised complication.
  • Richter transformation produces a more aggressive lymphoma.
  • Asymptomatic CLL usually does not require immediate treatment.
  • Modern treatment primarily involves targeted therapies rather than chlorambucil.
Most Important Examination Point

An older patient with incidentally discovered persistent lymphocytosis, small mature lymphocytes and smudge cells on peripheral blood film should raise suspicion of chronic lymphocytic leukaemia. Confirm the diagnosis using peripheral blood flow cytometry.

Clinical Note

Rapid lymph node enlargement, severe cytopenias, serious infections or new constitutional symptoms warrant prompt haematological assessment. Treatment should be individualised by a specialist haematology team.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments